Autres langues Alvotech

Actions

ALVO

LU2458332611

Recherche biotechnologique et médicale

Cours en clôture Nasdaq 23/09/2026			Varia. 5j.	Varia. 1 janv.
5,810 ^USD	-0,51%		+13,92%	+13,26%

22/09	Actions nordiques en Amérique du Nord - Ericsson progresse de 0,4 %	FW
18/09	Actions nordiques en Amérique du Nord - Ericsson recule de 0,4 %	FW

Autres langues

21/09	Alvotech(NasdaqGM:ALVO) added to S&P Global BMI Index
16/09	Alvotech Shares Rise After Double Upgrade From Barclays
16/09	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed's Rate Announcement
14/09	Certain Stock Options of Alvotech are subject to a Lock-Up Agreement Ending on 14-SEP-2026.
14/09	Certain Restricted Stock Units of Alvotech are subject to a Lock-Up Agreement Ending on 14-SEP-2026.
14/09	Certain Warrants of Alvotech are subject to a Lock-Up Agreement Ending on 14-SEP-2026.
14/09	Certain Ordinary Shares of Alvotech are subject to a Lock-Up Agreement Ending on 14-SEP-2026.
10/09	Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says
07/09	Takeda Files BPCIA Suit Against Alvotech For Vedolizumab Biosimilar
02/09	Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars
31/08	Alvotech Shares Rise After FDA Accepts Biologics License Application for AVT80
31/08	Alvotech's Application for Proposed Entyvio Biosimilar Accepted for US FDA Review
31/08	Alvotech Says FDA Accepted Biologics License Application for AVT80
31/08	Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations
31/08	Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80 Biosimilar to Entyvio
27/08	Alvotech to present at upcoming investor conferences in September
24/08	Alvotech's Q4 Approval, Launch Timelines Remain Intact, UBS Says
24/08	Lotus Pharmaceutical Announces Licensing and Commercialization Agreement with Alvotech for Biosimilar Candidates to Durvalumab and Emicizumab in the U.S. and Selected Asian Markets
24/08	Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
24/08	Lotus Pharma Unit to License Two Alvotech Biosimilars in $150 Million Deal
21/08	Alvotech And Lotus Pharmaceutical Enter Licensing And Commercialization Agreement For Proposed Biosimilars To Durvalumab And Emicizumab In The United States And Selected Asian Markets
21/08	Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets
21/08	Alvotech Signs Licensing Deal With Lotus Pharmaceutical for Proposed Biosimilars
21/08	Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
20/08	Alvotech Provides Earnings Guidance for the Full Year 2026